Akebia Therapeutics, Inc.
AKBAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2026 |
| BTIG | maintain | Buy | Nov 5, 2026 |
| BTIG | maintain | Buy | Sep 15, 2026 |
| Leerink Partners | downgrade | Outperform →Market Perform | Aug 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 1, 2026 |
| BTIG | maintain | Buy | Apr 7, 2026 |
| BTIG | maintain | Buy | Feb 25, 2026 |
| Piper Sandler | maintain | Overweight | Feb 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 6, 2026 |
| BTIG | maintain | Buy | Dec 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 30, 2025 |
| BTIG | maintain | Buy | Oct 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2025 |
| Piper Sandler | maintain | Overweight | Mar 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 23, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 15, 2024 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-0.04| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.04 | $-0.04 | $36.9M | $46.9M |
| Aug 5, 2026 | $-0.02 | $-0.04 | $49.1M | $48.9M |
| May 7, 2026 | $-0.03 | $-0.01 | $53.5M | $51.7M |
| Feb 26, 2026 | $-0.05 | $-0.03 | $57.6M | $46.1M |
| Nov 10, 2025 | $0.00 | $-0.06 | $58.8M | $48.4M |
| Aug 7, 2025 | $0.00 | $-0.02 | $62.5M | $47.9M |
| May 8, 2025 | $0.03 | $-0.03 | $57.3M | $50.8M |
| Mar 13, 2025 | $-0.10 | $-0.05 | $46.5M | $37.4M |
News
Akebia Therapeutics, Inc. ( AKBA ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Nicholas Grund - Senior VP & Chief Commercial Officer Steven Burke - Senior VP and Chief Research & Development Officer Conference Call Participants Andrew Kassin - BTIG, LLC, Research Division Nabeel Nissar - …
Akebia Therapeutics NASDAQ: AKBA reported lower third-quarter revenue and a net loss as sales of its kidney disease drug Auryxia fell and inventory reductions limited revenue growth for its anemia treatment Vafseo, despite a sharp increase in patients receiving the drug.
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline results from VOCAL, an open-label trial to evaluate the efficacy and safety of three times per week (TIW) dosing of vadadustat compared to the current standard of care erythropoiesis-stimulating agents (ESA) in patients with anemia due to chronic kidney disease (CKD) receiving in…
WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, prior to the open of financial markets.
Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026.
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 563…
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediat…
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on August 31, 2026.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.